VRAX Short Volume
Virax Biolabs Group Limited (VRAX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $526,283, listed on NASDAQ, employing roughly 26 people, carrying a beta of 1.34 to the broader market. Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Led by James Foster, public since 2022-07-21.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-08-28
- Short Volume
- 5.8K
- Total Volume
- 15.7K
- Short %
- 37.06%
- 30-Day Avg Short %
- 46.93%
Showing 30 days of FINRA short volume data for Virax Biolabs Group Limited.
Learn how short volume is reported and how to read the data →
Frequently asked VRAX short volume questions
- What is the daily VRAX short volume?
- As of Aug 28, 2026, Virax Biolabs Group Limited (VRAX) short volume is 5.8K shares against 15.7K total reported volume, or 37.06% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is VRAX short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does VRAX short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.